All In Biotech

Drug Trial Radar · NCT02128958

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis

Last checked: Nov 19, 2026Latest source record: Oct 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Sep 2014

Primary completion

Nov 27, 2017

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
May 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • CF102Drug

    orally q12h

  • PlaceboDrug

    orally q12 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Overall SurvivalTime frame: From date of first treatment (Cycle 1 Day 1) until date of death from any cause, assessed up to 12 months

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Simmons Cancer Center

    Dallas, Texas

  • Complex Oncology Center - Plovdiv

    Plovdiv, Bulgaria

  • Multiprofile Hospital for Active Treatment Central Onco Hospita

    Plovdiv, Bulgaria

  • Multiprofile Hospital for Active Treatment "Tokuda Hospital Sofia" AD

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment for women's health - Nadezhda

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment Serdica

    Sofia, Bulgaria

  • Multiprofile Hospital for Active Treatment "Sveta Marina" EAD

    Varna, Bulgaria

  • Rabin Medical Center

    Petah Tikva, Israel

  • Institutul Clinic Fundeni - Sectia Oncologie Medicala

    Bucharest, Romania

  • Clinica Bendis - Oncologie Medicala

    Cluj-Napoca, Romania

  • Centrul de Oncologie ONCOLAB

    Craiova, Romania

  • Institutul Regional de Oncologie Iasi - Sectia Oncologie Medicala

    Iași, Romania

  • Spitalul Pelican Impex SRL- Sectia Oncologie Medicala

    Oradea, Romania

  • SC DACMED SRL - Oncologie

    Ploieşti, Romania

  • Spitalului Clinic Judetean de Urgenta - Sectia Oncologie Medicala

    Sibiu, Romania

  • Spitalul Judetean de Urgenta "Sf. Ioan Cel Nou" - sectia Oncologie Medicala

    Suceava, Romania

  • Vojnomedicinska Akademija Beograd

    Belgrade, Serbia

  • Institut za Onkologiju Vojvodine

    Kamenitz, Serbia

  • Zdravstveni Centar Kladovo Služba Onkologije

    Kladovo, Serbia

  • Klinički Centar Niš Klinika za Onkologiju

    Niš, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.